Severe Cutaneous Adverse Reaction (SCAR) Clinical Research Consortium (CRC)

Grant number: U54 AI205728-01

NIH RePORTER

Principal Investigators

• Elizabeth Phillips, MD

Lead Institution: Vanderbilt University Medical Center

The Severe Cutaneous Adverse Drug Reactions Clinical Research Consortium (SCAR-CRC) brings together researchers, clinicians, patients, and advocacy groups across the United States to improve understanding and care of rare, serious cutaneous reactions to medications. Led by Vanderbilt University Medical Center, the consortium will follow patients over time, collect biological samples, and develop better tools to diagnose these conditions, identify the medications responsible, and assess disease severity and long-term outcomes. Through patient-centered research, education, and collaboration, SCAR-CRC aims to advance treatment and lay the groundwork for future clinical trials.

Diseases Studied

• Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN)
• Drug reaction with eosinophilia and systemic symptoms (DRESS)
• Acute generalized exanthematous pustulosis (AGEP)
• Generalized bullous fixed drug eruption (GBFDE)
• Severe cutaneous adverse reactions associated with immune checkpoint inhibitors (SCAR-iRAE)

Funding Statement

The Severe Cutaneous Adverse Reaction (SCAR) Clinical Research Consortium (CRC) is part of the Rare Diseases Clinical Research Network (RDCRN), which is funded by the National Institutes of Health (NIH) and led by the National Center for Advancing Translational Sciences (NCATS) through its Division of Rare Diseases Research Innovation (DRDRI). SCAR is funded under grant number U54AI205728 as a collaboration between NCATS, the National Institute of Allergy and Infectious Diseases (NIAID), and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This website is hosted by the network's Data Management and Coordinating Center at Cincinnati Children’s Hospital Medical Center, which is funded by NCATS and National Institute of Neurological Disorders and Stroke (NINDS) under grant number TR002818.